157 related articles for article (PubMed ID: 17712798)
1. Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells.
Forster MD; Ormerod MG; Agarwal R; Kaye SB; Jackman AL
Cytometry A; 2007 Nov; 71(11):945-50. PubMed ID: 17712798
[TBL] [Abstract][Full Text] [Related]
2. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies.
Figini M; Ferri R; Mezzanzanica D; Bagnoli M; Luison E; Miotti S; Canevari S
Gene Ther; 2003 Jun; 10(12):1018-25. PubMed ID: 12776159
[TBL] [Abstract][Full Text] [Related]
3. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.
Yuan Y; Nymoen DA; Dong HP; Bjørang O; Shih IeM; Low PS; Trope' CG; Davidson B
Hum Pathol; 2009 Oct; 40(10):1453-60. PubMed ID: 19454358
[TBL] [Abstract][Full Text] [Related]
4. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix.
Wu M; Gunning W; Ratnam M
Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):775-82. PubMed ID: 10498396
[TBL] [Abstract][Full Text] [Related]
5. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma.
Turk MJ; Waters DJ; Low PS
Cancer Lett; 2004 Sep; 213(2):165-72. PubMed ID: 15327831
[TBL] [Abstract][Full Text] [Related]
6. High-affinity folate receptor in human ovary, serous ovarian adenocarcinoma, and ascites: radioligand binding mechanism, molecular size, ionic properties, hydrophobic domain, and immunoreactivity.
Holm J; Hansen SI; Høier-Madsen M; Birn H; Helkjaer PE
Arch Biochem Biophys; 1999 Jun; 366(2):183-91. PubMed ID: 10356282
[TBL] [Abstract][Full Text] [Related]
7. Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor.
Figini M; Martin F; Ferri R; Luison E; Ripamonti E; Zacchetti A; Mortarino M; Di Cioccio V; Maurizi G; Allegretti M; Canevari S
Cancer Immunol Immunother; 2009 Apr; 58(4):531-46. PubMed ID: 18704410
[TBL] [Abstract][Full Text] [Related]
8. Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA Interference, on the activity of the new generation antifolate pemetrexed in HeLa cells.
Chattopadhyay S; Wang Y; Zhao R; Goldman ID
Clin Cancer Res; 2004 Dec; 10(23):7986-93. PubMed ID: 15585634
[TBL] [Abstract][Full Text] [Related]
9. Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative.
Ross TL; Honer M; Lam PY; Mindt TL; Groehn V; Schibli R; Schubiger PA; Ametamey SM
Bioconjug Chem; 2008 Dec; 19(12):2462-70. PubMed ID: 19053298
[TBL] [Abstract][Full Text] [Related]
10. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
Gibbs DD; Theti DS; Wood N; Green M; Raynaud F; Valenti M; Forster MD; Mitchell F; Bavetsias V; Henderson E; Jackman AL
Cancer Res; 2005 Dec; 65(24):11721-8. PubMed ID: 16357184
[TBL] [Abstract][Full Text] [Related]
11. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo.
Bottero F; Tomassetti A; Canevari S; Miotti S; Ménard S; Colnaghi MI
Cancer Res; 1993 Dec; 53(23):5791-6. PubMed ID: 8242637
[TBL] [Abstract][Full Text] [Related]
12. Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticles.
Schroeder JE; Shweky I; Shmeeda H; Banin U; Gabizon A
J Control Release; 2007 Dec; 124(1-2):28-34. PubMed ID: 17928088
[TBL] [Abstract][Full Text] [Related]
13. [The comparison of biological characteristics between tumor-infiltrating lymphocytes and tumor-associated lymphocytes in ascites of epithelial ovarian carcinoma].
Kang S; Shen K; Lang J
Zhonghua Fu Chan Ke Za Zhi; 1998 Oct; 33(10):607-10. PubMed ID: 10806687
[TBL] [Abstract][Full Text] [Related]
14. Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells.
Corona G; Giannini F; Fabris M; Toffoli G; Boiocchi M
Int J Cancer; 1998 Jan; 75(1):125-33. PubMed ID: 9426700
[TBL] [Abstract][Full Text] [Related]
15. A novel technique for the enrichment of primary ovarian cancer cells.
Chan JK; Hamilton CA; Anderson EM; Cheung MK; Baker J; Husain A; Teng NN; Kong CS; Negrin RS
Am J Obstet Gynecol; 2007 Nov; 197(5):507.e1-5. PubMed ID: 17980191
[TBL] [Abstract][Full Text] [Related]
16. Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography.
Li PY; Del Vecchio S; Fonti R; Carriero MV; Potena MI; Botti G; Miotti S; Lastoria S; Menard S; Colnaghi MI; Salvatore M
J Nucl Med; 1996 Apr; 37(4):665-72. PubMed ID: 8691264
[TBL] [Abstract][Full Text] [Related]
17. Tumor detection using folate receptor-targeted imaging agents.
Sega EI; Low PS
Cancer Metastasis Rev; 2008 Dec; 27(4):655-64. PubMed ID: 18523731
[TBL] [Abstract][Full Text] [Related]
18. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
Leamon CP; Reddy JA; Vetzel M; Dorton R; Westrick E; Parker N; Wang Y; Vlahov I
Cancer Res; 2008 Dec; 68(23):9839-44. PubMed ID: 19047164
[TBL] [Abstract][Full Text] [Related]
19. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.
Macor P; Mezzanzanica D; Cossetti C; Alberti P; Figini M; Canevari S; Tedesco F
Cancer Res; 2006 Apr; 66(7):3876-83. PubMed ID: 16585216
[TBL] [Abstract][Full Text] [Related]
20. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor.
Zhao XB; Lee RJ
Adv Drug Deliv Rev; 2004 Apr; 56(8):1193-204. PubMed ID: 15094215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
